Related references
Note: Only part of the references are listed.Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
Kerstin Trunzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Thomas Bachelot et al.
LANCET ONCOLOGY (2013)
Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
Eudocia Q. Lee et al.
CLINICAL CANCER RESEARCH (2012)
Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma
Tsuyoshi Fukushima et al.
NEURO-ONCOLOGY (2012)
Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome
Jean Y. Tang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer
Kunal S. Taskar et al.
PHARMACEUTICAL RESEARCH (2012)
Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study
Maryam Fouladi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report
Maryam Fouladi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS)
F Bai et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2006)
Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma
A Gajjar et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A clinicobiological model predicting survival in medulloblastoma
A Ray et al.
CLINICAL CANCER RESEARCH (2004)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
WL Xia et al.
ONCOGENE (2002)
Share Paper
